This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


GlaxoSmithKline plc

Drug Names(s): PPI-1019

Description: Apan specifically inhibits the aggregation of beta-amyloid and its associated nerve cell toxicity.

Deal Structure: Apan was developed by Praecis Pharmaceuticals until the company was aquired by GlaxoSmithKline in February 2007.

Apan News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug